# US 2021/0340630 A1 · Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340630 A1
- Document ID: US20210340630A1
- Status: Published application
- Kind: A1
- Application number: 17/307,236
- Filed: 2021-05-04
- Published: 2021-11-04
- Earliest claimed: 2018-11-22
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Applicants: Deutsches Krebs-Forschungszentrum Stiftung Des öFfentlichen Rechts
- Inventors: Antonio MARCHINI; Amit KULKARNI; Annabel GREWENIG; Jean ROMMELAERE; Tiina MARTTILA; Tiago FERREIRA
- Web page: https://patentgrep.com/patent/US20210340630A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- C12N 2750/14032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention concerns the use of laminins and/or galectins as biomarker(s) for predicting the outcome of the treatment with oncolytic parvovirus H1 (H-1 PV) in a cancer patient.

## Claims

### Claim 1

Use of a biomarker selected from the group consisting of laminin and/or galectin for predicting the outcome of the treatment with parvovirus H1 (H-1PV) of a patient suspected to suffer from a cancer.

### Claim 2 (depends on 1)

The use according to claim 1, wherein the laminin is LAMB1 and/or LAMC1.

### Claim 3 (depends on 1)

The use according to claim 1, wherein the galectin is LGALS1.

### Claim 4

A method of determining whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy for said cancer comprising the step of subjecting a patient's biological sample to at least one assay to measure the presence of a biomarker selected from the group consisting of laminin and/or galectin.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the laminin is LAMB1 and/or LAMC1.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the galectin is LGALS1.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the biological sample is a biopsy, blood, serum or plasma.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the cancer is a solid tumour.

### Claim 9 (depends on 8)

The method of claim 8, wherein the solid tumor is a brain cancer, lung cancer, breast cancer, skin cancer, colon cancer, pancreatic cancer or hepatocellular carcinoma.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the brain cancer is glioblastoma; wherein the lung cancer is non-small cell lung carcinoma; wherein the pancreatic cancer is pancreatic ductal adenocarcinoma, wherein the breast cancer is invasive ductal carcinoma, wherein the skin cancer is melanoma and wherein the colon cancer is colon adenocarcinoma.

### Claim 11 (depends on 10)

The method of claim 10, wherein the non-small lung carcinoma is lung adenocarcinoma or lung squamous cell carcinoma.

### Claim 12

A kit for predicting whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy, which kit comprises:
(a) means for measuring the level of a biomarker selected from the group consisting of laminins and/or galectins; and
b) optionally, a label giving instructions for the use of said kit in predicting whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy.
